Form 4: Neurocrine CCO Exercises Options, Sells Shares

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc. (NBIX), exercised 5,970 incentive stock options at an exercise price of $35.99 per share.
• Concurrently, he sold 5,970 shares of common stock at a weighted average sales price of $151.7388 per share, with individual sales ranging from $150.70 to $153.05.
• These transactions were executed on November 28, 2025, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Benevich on August 28, 2025.
• Following these transactions, Mr. Benevich directly holds 44,893 shares of common stock and 6,860 unexercised derivative securities (incentive stock options).
• His beneficial ownership prior to these transactions included an aggregate of 204 shares purchased through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan on February 28, 2025, and August 29, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of expiring stock options and an immediate sale of shares under a pre-arranged 10b5-1 plan. This is a common and expected event for executives managing their compensation and personal finances, and does not inherently signal strong positive or negative sentiment about the company's future prospects.

Positives

• The exercise of incentive stock options at a significantly lower price ($35.99) compared to the sale price ($151.7388) indicates a substantial profit realization for the executive.
• The transaction was conducted under a Rule 10b5-1 trading plan, which demonstrates a pre-planned and structured approach to managing personal equity holdings, mitigating concerns about opportunistic insider trading.

Negatives

• The direct beneficial ownership of common stock by the Chief Commercial Officer decreased by 5,970 shares following the sale.

Related Party Transactions

• The reporting person's beneficial ownership includes shares purchased through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan on February 28, 2025, and August 29, 2025.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Commercial Officer could be perceived as a slight reduction in insider alignment, though the transaction was pre-planned and routine.
• Employees: The Employee Stock Purchase Plan (ESPP) mentioned indicates a benefit available to employees, fostering broader employee ownership.

Key Dates

Recommendation

The filing details a routine insider transaction where an executive exercised expiring stock options and sold an equivalent number of shares under a pre-established 10b5-1 trading plan. Such transactions are common for executives managing their personal finances and equity compensation and typically do not provide new fundamental information to warrant a change in investment recommendation. The company's core business operations and future prospects remain the primary drivers for investment decisions.

Keywords

Neurocrine Biosciences, NBIX, Insider Transaction, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Eric Benevich, Chief Commercial Officer, Biotechnology